Flash Report 3 minutesRegister for Free AccessCVS Pharmacy [CVS] 3Q16 Results: Mixed Quarter; Company Reduces and Narrows Guidance Range Coresight Research November 9, 2016 Executive Summary CVS reported 3Q16 adjusted EPS of $1.64, up 28.0% year over year and beating the $1.57 consensus estimate. Revenues were $44.6 billion, up 15.5% year over year, missing the $45.3 billion consensus estimate. Pharmacy Services was the fastest-growing segment, with revenues up 19.2% year over year, to $30.4 billion; revenues in the Retail/Long-Term Care (LTC) segment grew by 12.5%. The company reduced and narrowed its 2016 adjusted EPS guidance range to $5.77–$5.83 from $5.81–$5.89. Preliminary 2017 adjusted EPS guidance is $5.77–$5.93, below the consensus estimate of $6.53. Please Login to read the full report. Not a member? To access this content for free, register for a free account. This document was generated for Other research you may be interested in: CES 2025 Wrap-Up: Top 10 Takeaways—AI, Retail Tech, Sustainability, and Health and Wellness Come into FocusThree Data Points We’re Watching This Week, Week 25: Predictive Data—Looking Ahead in US RetailUS CPG Sales Tracker: Sharp Beauty Rise Drives CPG Growth in December 2024Retail 2025: 10 AI Trends—An Inflection Point in the GenAI Revolution